Imaging Biomarkers in MASLD and Obesity Correlating Hepatic Fat Fraction, Adiposity Distribution, and Doppler Hemodynamic with Disease Severity
- A concise abstract
- A structured review/article outline
- A detailed literature review with recent evidence
- A research protocol, including imaging endpoints and statistical correlations
- A presentation or manuscript draft
Content of PPT: Title slide: Tilte, investigator, guide, department etc Aim and objectives Methodology Expected outcome References
MASLD imaging biomarkers MRI proton density fat fraction visceral adipose tissue Doppler hemodynamics disease severity review
MASLD imaging biomarkers
MASLD magnetic resonance proton density fat fraction visceral adipose tissue
https://pmc.ncbi.nlm.nih.gov/articles/PMC12865115
PMID: 39400428
MRI abdominal visceral adipose tissue subcutaneous adipose tissue segmentation diagram
~/
mkdir -p "/tmp/workspace/masld-imaging-ppt/src" "/tmp/workspace/masld-imaging-ppt/output" && python - <<'PY' from pptx import Presentation from pptx.util import Inches, Pt from pptx.dml.color import RGBColor from pptx.enum.text import PP_ALIGN, MSO_ANCHOR from pptx.enum.shapes import MSO_SHAPE from pptx.enum.dml import MSO_THEME_COLOR from pptx.enum.text import MSO_AUTO_SIZE out='/tmp/workspace/masld-imaging-ppt/output/MASLD_Imaging_Biomarkers_Research_Protocol.pptx' prs=Presentation(); prs.slide_width=Inches(13.333); prs.slide_height=Inches(7.5) blank=prs.slide_layouts[6] NAVY=RGBColor(14,45,70); TEAL=RGBColor(0,137,137); SKY=RGBColor(214,239,241); INK=RGBColor(35,48,58); MUTED=RGBColor(93,110,122); WHITE=RGBColor(255,255,255); GOLD=RGBColor(239,180,55); PALE=RGBColor(244,248,249) def rect(sl,x,y,w,h,color, radius=False): s=sl.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE if radius else MSO_SHAPE.RECTANGLE, Inches(x), Inches(y), Inches(w), Inches(h)); s.fill.solid();s.fill.fore_color.rgb=color;s.line.fill.background();return s def text(sl,x,y,w,h,txt,size=20,color=INK,bold=False,align=PP_ALIGN.LEFT, font='Aptos', valign=MSO_ANCHOR.TOP): tb=sl.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(h)); tf=tb.text_frame; tf.clear(); tf.word_wrap=True; tf.margin_left=Inches(.03);tf.margin_right=Inches(.03);tf.margin_top=Inches(.02);tf.margin_bottom=Inches(.02);tf.vertical_anchor=valign for i,line in enumerate(txt.split('\n')): p=tf.paragraphs[0] if i==0 else tf.add_paragraph();p.text=line;p.alignment=align;p.space_after=Pt(4) for r in p.runs:r.font.name=font;r.font.size=Pt(size);r.font.bold=bold;r.font.color.rgb=color return tb def bullet(sl,x,y,w,h,items,size=19): tb=sl.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(h));tf=tb.text_frame;tf.clear();tf.word_wrap=True;tf.margin_left=Inches(.04);tf.margin_right=Inches(.04) for i,item in enumerate(items): p=tf.paragraphs[0] if i==0 else tf.add_paragraph();p.text=item;p.level=0;p.font.size=Pt(size);p.font.name='Aptos';p.font.color.rgb=INK;p.space_after=Pt(10);p._p.get_or_add_pPr().insert(0, __import__('pptx').oxml.xmlchemy.OxmlElement('a:buChar')); # fails? return tb def title(sl,kicker,heading,sub=''): rect(sl,0,0,13.333,.22,TEAL); text(sl,.65,.46,12,.28,kicker.upper(),11,TEAL,True);text(sl,.65,.78,12,0.72,heading,30,NAVY,True); if sub:text(sl,.67,1.5,11.8,.45,sub,14,MUTED) rect(sl,.65,2.05,1.15,.06,GOLD) def footer(sl,num): text(sl,.65,7.15,6,.2,'Department of Radiodiagnosis | Research Protocol',9,MUTED);text(sl,12.2,7.15,.45,.2,str(num),9,MUTED,True,PP_ALIGN.RIGHT) # 1 s=prs.slides.add_slide(blank);rect(s,0,0,13.333,7.5,NAVY);rect(s,0,0,13.333,.18,TEAL);rect(s,.78,1.12,.12,4.55,GOLD) text(s,1.18,1.18,11.1,.35,'RESEARCH PROTOCOL',13,RGBColor(150,221,220),True) text(s,1.18,1.7,10.9,1.55,'Imaging Biomarkers in MASLD and Obesity',34,WHITE,True) text(s,1.18,3.2,10.6,.75,'Correlation of hepatic fat fraction, adiposity distribution, and Doppler hemodynamics with disease severity',20,RGBColor(219,234,239)) rect(s,1.18,4.55,10.5,.02,RGBColor(81,123,145));text(s,1.18,4.9,10.4,.9,'Investigator: [Name]\nGuide: [Name and Designation]\nDepartment of Radiodiagnosis, [Institution]',18,WHITE) text(s,1.18,6.62,10,.25,'[Month Year]',12,RGBColor(150,221,220)) # 2 aim s=prs.slides.add_slide(blank);title(s,'Study premise','Aim and objectives','Non-invasive, quantitative imaging phenotype of MASLD in adults with obesity') rect(s,.68,2.35,12,1.03,SKY,True);text(s,.98,2.56,11.4,.48,'Aim: To assess the relationship of imaging biomarkers of hepatic steatosis, adiposity distribution, and hepatic Doppler hemodynamics with MASLD disease severity.',19,NAVY,True) text(s,.7,3.78,5.8,.3,'PRIMARY OBJECTIVES',13,TEAL,True);text(s,6.9,3.78,5.5,.3,'SECONDARY OBJECTIVES',13,TEAL,True) for x,y,w,h,head,body in [(.7,4.18,5.7,.88,'01 Hepatic fat','Quantify hepatic fat fraction using MRI-PDFF and correlate it with steatosis grade and fibrosis risk.'),(.7,5.2,5.7,.88,'02 Adiposity distribution','Measure visceral and subcutaneous adipose tissue and examine their association with hepatic fat fraction.'),(6.9,4.18,5.7,.88,'03 Hemodynamics','Evaluate portal-vein and hepatic-vein Doppler indices in relation to fat burden and fibrosis risk.'),(6.9,5.2,5.7,.88,'04 Integrated phenotype','Develop an imaging-based model for stratification of MASLD severity.')]: rect(s,x,y,w,h,PALE,True);text(s,x+.23,y+.14,w-.45,.22,head,15,NAVY,True);text(s,x+.23,y+.4,w-.45,.37,body,13,INK) footer(s,2) #3 s=prs.slides.add_slide(blank);title(s,'Design','Methodology','Prospective cross-sectional observational study') # flow labels=[('Population','Adults with obesity\nand suspected/known MASLD'),('Clinical & labs','Anthropometry, metabolic profile,\nLFTs, FIB-4 / ELF if available'),('Imaging','US + Doppler\nMRI-PDFF ± MRE'),('Analysis','Correlation, regression,\nseverity stratification')] for i,(h,b) in enumerate(labels): x=.68+i*3.12;rect(s,x,2.45,2.65,1.22,PALE,True);text(s,x+.16,2.66,2.34,.22,h,15,NAVY,True,PP_ALIGN.CENTER);text(s,x+.14,2.98,2.36,.45,b,12,INK,False,PP_ALIGN.CENTER) if i<3:text(s,x+2.71,2.85,.28,.25,'›',28,TEAL,True,PP_ALIGN.CENTER) text(s,.7,4.05,4,.25,'ELIGIBILITY',13,TEAL,True);text(s,4.75,4.05,4,.25,'EXCLUSIONS',13,TEAL,True);text(s,8.8,4.05,4,.25,'REFERENCE STANDARD',13,TEAL,True) for x,lines in [(.7,['Age ≥18 years','Obesity by BMI or central obesity','MASLD on clinical and/or imaging assessment']),(4.75,['Significant alcohol intake','Other chronic liver disease','Pregnancy or MRI contraindication']),(8.8,['Histology where clinically available','Otherwise composite: MRI-PDFF, MRE/liver stiffness, laboratory fibrosis risk score'])]: rect(s,x,4.42,3.72,1.65,WHITE,True);text(s,x+.18,4.62,3.32,1.2,'• '+'\n• '.join(lines),14,INK) footer(s,3) #4 biomarkers s=prs.slides.add_slide(blank);title(s,'Imaging protocol','Acquisition and imaging biomarkers','Standardize fasting status, scanner settings, acquisition planes, and Doppler angle correction') cols=[('Hepatic fat fraction','MRI-PDFF\nWhole-liver ROI or automated segmentation\nPrimary quantitative steatosis biomarker'),('Adiposity distribution','MRI or CT-derived VAT and SAT area/volume\nVAT/SAT ratio\nWaist circumference as clinical comparator'),('Doppler hemodynamics','Portal vein diameter, velocity and flow\nPortal-vein pulsatility index\nHepatic-vein waveform; splenic indices if feasible')] for i,(h,b) in enumerate(cols): x=.72+i*4.12;rect(s,x,2.4,3.7,2.35,PALE,True);rect(s,x,2.4,3.7,.12,[TEAL,GOLD,NAVY][i]);text(s,x+.25,2.72,3.15,.3,h,18,NAVY,True);text(s,x+.25,3.25,3.15,1.05,b,14,INK) text(s,.7,5.35,11.8,.3,'Disease-severity endpoints',13,TEAL,True);rect(s,.7,5.68,11.85,.7,SKY,True);text(s,.95,5.89,11.3,.28,'Steatosis severity | Liver stiffness / fibrosis risk | Presence of MASH-risk phenotype | Metabolic comorbidity burden',16,NAVY,True,PP_ALIGN.CENTER) footer(s,4) #5 analysis s=prs.slides.add_slide(blank);title(s,'Analysis plan','Data handling and statistics','Primary analytic question: do MRI-PDFF, visceral adiposity, and Doppler measures independently track disease severity?') steps=[('1','Descriptive','Distribution of imaging, laboratory, and clinical variables.'),('2','Correlation','Pearson or Spearman correlation of MRI-PDFF, VAT/SAT and Doppler indices with severity endpoints.'),('3','Group comparison','Compare biomarker values across steatosis and fibrosis-risk categories.'),('4','Multivariable model','Regression adjusted for age, sex, BMI, diabetes, and metabolic covariates.'),('5','Performance','ROC analysis for a composite imaging biomarker model; report AUC, CI, sensitivity and specificity.')] for i,(n,h,b) in enumerate(steps): y=2.18+i*.83;rect(s,.72,y,.46,.46,TEAL,True);text(s,.72,y+.08,.46,.2,n,13,WHITE,True,PP_ALIGN.CENTER);text(s,1.38,y,2.3,.22,h,15,NAVY,True);text(s,3.65,y,8.45,.35,b,14,INK) footer(s,5) #6 expected s=prs.slides.add_slide(blank);title(s,'Anticipated contribution','Expected outcome','A practical, non-invasive imaging framework for phenotyping MASLD in obesity') for i,(h,b) in enumerate([('Quantitative correlation','Higher MRI-PDFF and visceral adiposity are expected to associate with greater steatosis burden and adverse metabolic profile.'),('Hemodynamic signal','Doppler alterations may add physiologic information, particularly as fibrosis risk or portal resistance increases.'),('Risk stratification','A multiparametric model may outperform any individual imaging measure for identifying higher-risk participants.'),('Clinical relevance','Results can guide selection for elastography, hepatology referral, biopsy consideration, and longitudinal monitoring.')]): x=.72+(i%2)*6.05;y=2.35+(i//2)*1.56;rect(s,x,y,5.65,1.23,PALE,True);text(s,x+.22,y+.18,5.15,.25,h,17,NAVY,True);text(s,x+.22,y+.55,5.12,.5,b,13,INK) rect(s,.72,5.9,11.7,.58,SKY,True);text(s,.9,6.06,11.3,.22,'Caution: cross-sectional associations cannot establish causality; Doppler findings should be interpreted as adjunctive rather than stand-alone markers of MASLD severity.',12,NAVY,False,PP_ALIGN.CENTER) footer(s,6) #7 refs s=prs.slides.add_slide(blank);title(s,'Sources','References','Key background and methodological sources') refs=[ 'Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of NAFLD. Hepatology. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323.', 'European Association for the Study of the Liver, et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol. 2024;81:492-542.', 'Cathcart J, et al. Accuracy of non-invasive imaging techniques for the diagnosis of MASH in patients with MASLD: a systematic review. Liver Int. 2025;45:e16127. doi:10.1111/liv.16127. PMID: 39400428.', 'Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging. 2012;36:1011-1014. doi:10.1002/jmri.23741.', 'Gul D, et al. Imaging biomarkers in metabolic dysfunction-associated steatotic liver disease. Front Med. 2025. (Review of MR biomarkers in MASLD).', 'Yamada’s Textbook of Gastroenterology, 7th ed. Hepatic steatosis and MRI assessment. p. 2757.' ] for i,r in enumerate(refs): y=2.18+i*.65;rect(s,.72,y,.32,.32,TEAL,True);text(s,.72,y+.055,.32,.17,str(i+1),10,WHITE,True,PP_ALIGN.CENTER);text(s,1.18,y-.02,11.25,.48,r,11.5,INK) text(s,.72,6.52,11.55,.24,'Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; PDFF, proton density fat fraction; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.',10,MUTED) footer(s,7) prs.save(out) print(out) PY python - <<'PY' from pptx import Presentation p='/tmp/workspace/masld-imaging-ppt/output/MASLD_Imaging_Biomarkers_Research_Protocol.pptx' prs=Presentation(p) print('slides',len(prs.slides)) for i,s in enumerate(prs.slides,1): print(i, len(s.shapes), ' | '.join(sh.text[:35].replace('\n',' ') for sh in s.shapes if getattr(sh,'has_text_frame',False))[:150]) PY
MASLD Imaging Biomarkers Research Protocol
Presentation · PPTX
- Title slide with placeholders for investigator, guide, department, institution, and date
- Aim and objectives
- Methodology and eligibility framework
- Imaging biomarkers and acquisition protocol
- Statistical analysis plan
- Expected outcomes and limitations
- References, including current MASLD guidance and a 2025 systematic review of imaging for MASH/MASLD.
I want content
MASLD imaging biomarkers
2024 EASL EASD EASO clinical practice guidelines MASLD imaging MRI-PDFF elastography
Slide 1: Title Slide
Correlation of Hepatic Fat Fraction, Adiposity Distribution, and Doppler Hemodynamics with Disease Severity
Guide: Dr. [Guide Name], [Designation]
Department: Department of Radiodiagnosis
Institution: [Institution Name]
Date: [Month, Year]
Slide 2: Aim and Objectives
Aim
Objectives
-
To quantify hepatic fat fraction using MRI proton density fat fraction (MRI-PDFF).
-
To assess adiposity distribution by measuring visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and the VAT/SAT ratio.
-
To evaluate hepatic and portal Doppler hemodynamics, including portal vein diameter, mean velocity, flow direction, pulsatility index, and hepatic vein waveform.
-
To correlate imaging biomarkers with clinical, biochemical, and non-invasive fibrosis indicators, including liver stiffness measurement and FIB-4 score.
-
To identify an imaging-based multiparametric profile associated with greater MASLD severity and fibrosis risk.
Slide 3: Methodology
Study Design
- Prospective cross-sectional observational study.
Study Population
- Adults aged 18 years or older with obesity and suspected or established MASLD.
- Participants will be recruited from radiology, hepatology, gastroenterology, and obesity clinics.
Inclusion Criteria
- Age ≥18 years.
- Obesity, defined by BMI ≥30 kg/m² or central obesity according to applicable ethnic cutoffs.
- Evidence of hepatic steatosis on ultrasound, MRI, or previous imaging.
- At least one cardiometabolic risk factor, such as type 2 diabetes mellitus, hypertension, dyslipidemia, or increased waist circumference.
Exclusion Criteria
- Significant alcohol intake.
- Viral hepatitis, autoimmune hepatitis, Wilson disease, hemochromatosis, or other chronic liver diseases.
- Known hepatic malignancy or portal-vein thrombosis.
- Pregnancy.
- Contraindication to MRI.
Clinical and Laboratory Assessment
- Age, sex, body mass index, waist circumference, and waist-to-hip ratio.
- History of diabetes mellitus, hypertension, dyslipidemia, and medication use.
- Liver function tests: AST, ALT, bilirubin, albumin, alkaline phosphatase, and GGT.
- Platelet count, fasting blood glucose, HbA1c, fasting insulin, lipid profile.
- FIB-4 score and, where available, enhanced liver fibrosis test or elastography-derived stiffness.
Slide 4: Imaging Protocol and Biomarkers
A. Hepatic Fat Fraction
- MRI-PDFF will be performed using a multiecho chemical-shift encoded MRI sequence.
- Hepatic fat fraction will be recorded as a percentage using whole-liver or standardized multi-segment region-of-interest measurements.
- MRI-PDFF is a quantitative, non-invasive technique for detecting and measuring liver fat and is more accurate than conventional ultrasound for mild steatosis.
B. Adiposity Distribution
- Abdominal MRI or CT images will be used to quantify:
- Visceral adipose tissue area or volume
- Subcutaneous adipose tissue area or volume
- VAT/SAT ratio
- Measurements may be obtained at the L3 vertebral level or using volumetric segmentation, depending on protocol availability.
- Visceral adiposity is expected to show a stronger association with hepatic steatosis and metabolic dysfunction than BMI alone.
C. Doppler Hemodynamic Evaluation
- Doppler ultrasound will assess:
- Main portal vein diameter
- Mean portal vein velocity
- Portal venous flow direction
- Portal vein pulsatility index
- Hepatic vein waveform pattern
- Splenic vein velocity and splenic size, where feasible
- A reduced portal flow velocity, altered venous pulsatility, or abnormal hepatic vein waveform may reflect altered hepatic vascular compliance or advancing fibrosis.
D. Disease-Severity Assessment
- Steatosis grade based on MRI-PDFF.
- Liver stiffness assessment by transient elastography or MR elastography, where available.
- Non-invasive fibrosis risk category based on FIB-4.
- Presence of metabolic comorbidities and biochemical liver injury.
Slide 5: Statistical Analysis
-
Data will be summarized as mean ± standard deviation or median with interquartile range for continuous variables, and frequency with percentage for categorical variables.
-
Normality of data will be assessed using the Shapiro-Wilk test.
-
Correlation between MRI-PDFF, VAT, SAT, VAT/SAT ratio, Doppler indices, and disease-severity variables will be assessed using:
- Pearson correlation for normally distributed data
- Spearman rank correlation for non-normally distributed data
-
Participants will be categorized by:
- Steatosis severity
- Low, intermediate, or high fibrosis risk
- Liver stiffness category
-
Intergroup comparisons will be performed using:
- Independent t-test or Mann-Whitney U test for two groups
- ANOVA or Kruskal-Wallis test for more than two groups
- Chi-square test for categorical variables
-
Multivariable linear or logistic regression will determine whether hepatic fat fraction, visceral adiposity, and Doppler parameters independently predict disease severity after adjustment for age, sex, BMI, diabetes, and dyslipidemia.
-
Receiver operating characteristic analysis may be used to assess the diagnostic performance of combined imaging biomarkers for identifying higher fibrosis-risk disease.
-
A p-value <0.05 will be considered statistically significant.
Slide 6: Expected Outcome
-
Hepatic fat fraction
- MRI-PDFF is expected to correlate positively with the degree of hepatic steatosis and adverse metabolic characteristics.
-
Visceral adiposity
- VAT and a higher VAT/SAT ratio are expected to be more strongly associated with hepatic fat accumulation and fibrosis risk than BMI alone.
-
Doppler biomarkers
- Portal venous flow and hepatic venous waveform parameters may demonstrate changes with increasing disease severity, especially in patients with higher liver stiffness or fibrosis risk.
-
Multiparametric imaging phenotype
- A combination of MRI-PDFF, adiposity-distribution measures, and Doppler hemodynamics may provide better severity stratification than a single imaging biomarker.
-
Clinical application
- The study may support a non-invasive imaging pathway for identifying obese patients with MASLD who need elastography, hepatology referral, closer surveillance, or possible biopsy.
Expected Conclusion
Slide 7: References
-
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323.
-
European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.
-
Cathcart J, Barrett R, Bowness JS, et al. Accuracy of non-invasive imaging techniques for the diagnosis of MASH in patients with MASLD: A systematic review. Liver International. 2025;45:e16127. doi:10.1111/liv.16127. PMID: 39400428. The review found promising MRI and ultrasound approaches, but also emphasized that most studies lacked independent prospective validation.
-
Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. Journal of Magnetic Resonance Imaging. 2012;36(5):1011-1014. doi:10.1002/jmri.23741.
-
Grainger & Allison’s Diagnostic Radiology. 7th ed. Section: Hepatic Steatosis. MRI chemical-shift imaging is described as highly sensitive and specific for hepatic steatosis.
-
Yamada’s Textbook of Gastroenterology. 7th ed. Section: Serum-based diagnosis of steatosis. MRI-PDFF is described as a superior method for detection and quantification of hepatic steatosis.
Continue
- Introduction and rationale
- Detailed methodology, including sample size and imaging protocol
- Hypothesis and variables
- Ethics, limitations, and timeline
- Speaker notes for each PPT slide
Write a detailed methodology with sample size
MASLD imaging biomarkers MRI-PDFF systematic review
EASL EASD EASO 2024 MASLD guidelines MRI PDFF elastography FIB-4 recommendations
Detailed Methodology
1. Study Design
- Hepatic fat fraction measured by MRI proton density fat fraction (MRI-PDFF)
- Visceral and subcutaneous adiposity distribution
- Hepatic and portal Doppler hemodynamic parameters
- MASLD severity, assessed by steatosis severity, liver stiffness, and non-invasive fibrosis risk scores
2. Study Setting and Duration
- Setting: Department of Radiodiagnosis, [Institution Name].
- Study period: [12-18 months], following Institutional Ethics Committee approval.
- Study population: Consecutive eligible adults attending radiology, medicine, endocrinology, gastroenterology, obesity, or hepatology clinics.
3. Study Population
Inclusion Criteria
- Adults aged 18 years or older.
- Obesity, defined as either:
- BMI ≥30 kg/m², or
- For an Asian Indian population, BMI ≥25 kg/m² or central obesity as per ethnic-specific criteria.
- Evidence of hepatic steatosis on prior ultrasound, CT, MRI, controlled attenuation parameter, or MRI-PDFF.
- At least one cardiometabolic risk factor:
- Type 2 diabetes mellitus
- Prediabetes
- Hypertension
- Dyslipidemia
- Increased waist circumference
- Hypertriglyceridemia
- Willingness to provide written informed consent and undergo ultrasound, Doppler examination, and MRI.
Exclusion Criteria
- Significant alcohol consumption, according to locally adopted MASLD diagnostic criteria.
- Viral hepatitis B or C infection.
- Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency, or other chronic liver diseases.
- Drug-induced steatosis or hepatotoxic drug exposure, where clinically relevant.
- Known hepatocellular carcinoma, hepatic metastases, portal vein thrombosis, or Budd-Chiari syndrome.
- Decompensated cirrhosis with ascites, encephalopathy, or variceal bleeding.
- Pregnancy.
- Contraindication to MRI, such as a non-MRI-compatible implant, severe claustrophobia, or inability to lie supine.
- Technically inadequate Doppler examination or non-diagnostic MRI.
4. Sample Size Calculation
- Expected minimum clinically meaningful correlation coefficient: r = 0.30
- Type I error: α = 0.05, two-sided
- Power: 80%
- (Z_{\alpha/2} = 1.96)
- (Z_{\beta} = 0.84)
Final Proposed Sample Size
5. Clinical and Anthropometric Assessment
Demographic Data
- Age
- Sex
- Occupation
- Relevant medical and family history
Anthropometric Parameters
- Height in metres
- Weight in kilograms
- Body mass index:
- Waist circumference
- Hip circumference
- Waist-to-hip ratio
Clinical Data
- Type 2 diabetes mellitus
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea, if present
- Current medication history
- Alcohol consumption history
- Duration of obesity and metabolic disease
6. Laboratory Evaluation
Routine Investigations
- Hemoglobin and total leukocyte count
- Platelet count
- Serum AST and ALT
- Serum bilirubin
- Alkaline phosphatase
- Gamma-glutamyl transferase
- Serum albumin
- Fasting plasma glucose
- HbA1c
- Fasting lipid profile
- Fasting insulin, where available
Non-Invasive Fibrosis Score
7. Ultrasound and Doppler Examination
Equipment
- High-resolution ultrasound machine
- Curvilinear transducer, approximately 2-5 MHz
- Doppler settings standardized for all participants
Grayscale Ultrasound Assessment
- Liver size and echogenicity
- Hepatorenal echogenic contrast
- Posterior beam attenuation
- Intrahepatic vascular blurring
- Splenic size
- Surface nodularity, if present
- Ascites, if present
Doppler Protocol
- Portal vein diameter in millimetres.
- Mean portal vein velocity in cm/s.
- Direction of portal venous flow:
- Hepatopetal
- Hepatofugal
- To-and-fro flow, if present
- Portal vein pulsatility index:
- Hepatic vein waveform:
- Triphasic
- Biphasic
- Monophasic
- Splenic vein velocity, where technically feasible.
- Hepatic artery resistive index, optionally:
8. Liver Stiffness Assessment
- Vibration-controlled transient elastography (VCTE/FibroScan), or
- MR elastography, if available.
- Participants will fast for at least 3 hours.
- Ten valid measurements will be obtained.
- Interquartile range/median ratio and success rate will be documented for quality assurance.
- The XL probe will be used where appropriate in obesity.
9. MRI Protocol
Patient Preparation
- Fasting for 4-6 hours before MRI.
- Supine position.
- Breath-hold instructions provided before acquisition.
MRI Sequences
- Axial T1-weighted in-phase and opposed-phase imaging.
- Axial T2-weighted imaging with or without fat suppression.
- Multiecho chemical-shift encoded MRI sequence for MRI-PDFF mapping.
- MR elastography, where available.
- Axial images through the abdomen at the L3 vertebral level for adipose-tissue measurement.
Hepatic Fat Fraction Measurement
- T2* decay
- T1 bias
- Spectral complexity of fat
- Eddy-current effects
- Major vessels
- Bile ducts
- Focal lesions
- Areas of artifact
- Liver edge
10. Adiposity Distribution Analysis
Parameters
- Visceral adipose tissue area or volume
- Subcutaneous adipose tissue area or volume
- Total abdominal adipose tissue
- Visceral-to-subcutaneous adipose tissue ratio
11. Disease Severity Classification
A. Steatosis Severity
- Based primarily on MRI-PDFF values.
- MRI-PDFF will be analyzed both as a continuous variable and as a categorical severity marker based on locally accepted or literature-supported thresholds.
B. Fibrosis Risk
- Low-risk, intermediate-risk, or high-risk category based on FIB-4 and liver stiffness measurement.
- The FIB-4 plus elastography strategy is supported by current European MASLD guidance.
C. Composite MASLD Severity
- Higher MRI-PDFF
- Increased liver stiffness
- Intermediate or high FIB-4 risk
- Type 2 diabetes mellitus
- Visceral obesity
- Persistent elevation of ALT or AST
12. Outcome Variables
Primary Outcome
Secondary Outcomes
- Correlation of MRI-PDFF with visceral adipose tissue, subcutaneous adipose tissue, and VAT/SAT ratio.
- Correlation of Doppler parameters with MRI-PDFF and liver stiffness.
- Comparison of imaging biomarkers across FIB-4 fibrosis-risk categories.
- Identification of independent predictors of high fibrosis-risk phenotype.
- Diagnostic performance of combined MRI-PDFF, VAT/SAT ratio, and Doppler indices for identifying high-risk MASLD.
13. Statistical Analysis
- Statistical analysis will be performed using SPSS, R, Stata, or equivalent software.
- Continuous variables will be expressed as mean ± standard deviation for normally distributed data and median with interquartile range for skewed data.
- Categorical variables will be expressed as frequency and percentage.
- Normality will be assessed using the Shapiro-Wilk test.
Analytical Tests
- Pearson correlation for normally distributed continuous variables.
- Spearman rank correlation for skewed continuous or ordinal variables.
- Independent t-test or Mann-Whitney U test for comparison between two groups.
- One-way ANOVA or Kruskal-Wallis test for comparison among more than two groups.
- Chi-square test or Fisher exact test for categorical variables.
- Multivariable linear regression to identify predictors of MRI-PDFF and liver stiffness.
- Multivariable logistic regression for high fibrosis-risk phenotype.
- Receiver operating characteristic curve analysis to evaluate discriminatory performance of individual and combined imaging biomarkers.
- Age
- Sex
- BMI
- Waist circumference
- Type 2 diabetes mellitus
- Hypertension
- Dyslipidemia
- ALT level
14. Quality Control
- All Doppler examinations will use a uniform acquisition protocol.
- Doppler measurements will be performed in triplicate, with mean values used for analysis.
- MRI-PDFF regions of interest will avoid vessels, lesions, and artifacts.
- A subset of approximately 20% of examinations may be re-read by a second radiologist to assess interobserver agreement.
- Interobserver agreement can be assessed using intraclass correlation coefficient for continuous measures and Cohen kappa for categorical findings.
- Image reviewers should be blinded to FIB-4 values and laboratory results where feasible.
15. Ethical Considerations
- Institutional Ethics Committee approval will be obtained before participant recruitment.
- Written informed consent will be obtained from every participant.
- Participant data will be anonymized and stored securely.
- MRI does not involve ionizing radiation.
- Imaging findings requiring clinical attention, such as advanced fibrosis, cirrhosis, focal lesion, or portal-vein thrombosis, will be communicated to the treating physician.
Short Methodology for a PPT Slide
Sample size: 100 participants, calculated to detect a correlation of r = 0.30 between MRI-PDFF and liver stiffness at 80% power and 5% alpha, including 15% attrition.
Participants: Adults with obesity and MASLD after exclusion of significant alcohol use and alternate chronic liver diseases.
Assessment: Clinical profile, anthropometry, liver biochemistry, FIB-4, ultrasound with portal/hepatic Doppler, VCTE/MRE, MRI-PDFF, and MRI-based VAT/SAT quantification.
Primary outcome: Correlation between hepatic fat fraction and liver stiffness.
Statistics: Correlation tests, group comparison, multivariable regression, ROC analysis, p <0.05.
Can you calculate sample size of 40 for this
sample size correlation Fisher z formula statistical power n 40 alpha 0.05
MASLD imaging biomarkers
Sample Size Calculation
Assumptions
- Expected correlation coefficient: r = 0.45
- Level of significance: α = 0.05, two-sided
- Study power: 80%
- (Z_{\alpha/2} = 1.96)
- (Z_{\beta} = 0.84)
Text for Methodology
The sample size was calculated for the primary objective of assessing the correlation between MRI-derived hepatic fat fraction and MASLD severity. Assuming an anticipated moderate correlation coefficient of 0.45, with a two-sided alpha level of 0.05 and 80% power, the minimum calculated sample size was 37 participants using Fisher's Z transformation. After allowing for approximately 8% non-evaluable or incomplete data, the final sample size was fixed at 40 participants.